US-UK Trade Agreement Raises NICE QALY Threshold to Expand Drug Access in UK

A recent US-UK trade agreement has introduced significant changes to pharmaceutical pricing and access policies. The deal requires the UK’s National Institute for Health and Care Excellence (NICE) to increase its Quality-Adjusted Life Year (QALY) threshold, a metric used to evaluate the cost-effectiveness of drugs. This adjustment is expected to expand access to innovative treatments in the UK market. Additionally, Eli Lilly has announced further price reductions for its GLP-1 medications, while researchers have confirmed a link between respiratory syncytial virus (RSV) infections and asthma development.

The QALY threshold change under the trade agreement aims to facilitate broader availability of cutting-edge therapies by altering NICE’s evaluation criteria. This move could potentially allow more high-cost drugs to be approved for use within the UK healthcare system. Meanwhile, Eli Lilly continues its efforts to make GLP-1 drugs more affordable by deepening price cuts, following previous measures aimed at improving accessibility for patients managing diabetes and obesity. Separately, scientific studies have established a connection between RSV infections and an increased risk of developing asthma later in life, providing new insights into respiratory health and disease prevention strategies.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: December 2, 2025

Related posts:

Academics Suggest Compulsory Licenses for Gilead’s HIV Prevention Drug to Increase Access in Low-Resource Countries Abdominal Fat Linked to Greater Blood Vessel Damage Than Subcutaneous Fat Study Identifies PRDM6 as a Methylation Regulator Protecting Against Polycystic Ovary Syndrome Study Links Oxytocin Effectiveness to Time of Day in Patients with Gestational Diabetes

Author

GOAI